AmerisourceBergen To Pay $260 Million in Guilty Plea Over Syringes

AmerisourceBergen To Pay $260 Million in Guilty Plea Over Syringes

AmerisourceBergen Specialty Group pleaded guilty to selling misbranded drugs and agreed to pay $260 million in penalties.  In court documents, the company admitted that a former subsidiary had packaged syringes of cancer drugs at a facility no registered with the U.S. Food and Drug Administration, that it filled syringes in excess of safe doses, and that it dispensed syringes based on prescriptions not signed by medical practitioners.  Federal prosecutors also alleged that the subsidiary prepared syringes by pooling single-use glass vials in a non-sterile environment.  [9/28/17]

Search